Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial (NCT07020559) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial
China56 participantsStarted 2026-04
Plain-language summary
Diabetic wounds are difficult to heal. Autologous platelets in diabetic patients with renal insufficiency have poor function. Allogeneic platelet plasma has a promising application prospect. Comparing the efficacy and safety differences between allogeneic platelet plasma and autologous platelet plasma is of significant importance and value for the clinical application.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. The patient is aged 18-80 years old;
✓. Diagnosed as type 1 or type 2 diabetes according to the World Health Organization standard, blood sugar has been controlled before enrollment, and the level of Glycated hemoglobin HbA1c is less than 10%;
✓. Abnormal renal function defined as:
✓. The patient has diabetes wounds with poor healing or prolonged healing need standard wound treatment;
✓. After preparing the wound bed, the condition for using platelet plasma to close the wound is met\*;
✓. Voluntarily sign an informed consent form;
Exclusion criteria
✕. Blood glucose is out of control or not yet effectively controlled，;
✕. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;
✕. Active bleeding inside the wound, and routine basic treatment plans cannot be implemented；
✕. Uncontrolled systemic or disseminated infections;
✕. Patients with advanced malignant tumors;
✕. Pregnant or lactating women；
✕. The patient is unable to cooperate or has mental disorders;
What they're measuring
1
the wound healing rate at 4 weeks
Timeframe: by the end of 4 weeks
Trial details
NCT IDNCT07020559
SponsorPeking University Third Hospital
Sponsor typeOTHER
Study typeINTERVENTIONAL
Primary completion2027-12
Contact for this trial
Long Zhang Executive Deputy Director, Medical Doctor
✕. According to the judgment of the researchers, the patient has a clear and irremovable cause that affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.